MyChesCo on MSN14h
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial
New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
AstraZeneca’s potential blockbuster pill halves high cholesterol
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...
AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial
AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
Fierce Biotech7d
AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...
Yahoo Finance6d
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
AstraZeneca's executive vice president Sharon Barr said: “These new data reflect AZD0780’s ability to reduce LDL cholesterol in patients who need more options to manage their cholesterol and ...
pharmaphorum6d
ACC25: AZ stakes its claim to the oral PCSK9 category
AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...
Stock Movers: Astrazeneca, Tesco, Travis Perkins
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
NBC Washington6d
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...